UK:
Medical Device Issuer Becomes First Regulation A+ Issuer To Seek NYSE Market Listing
14 September 2017
Withers LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Myomo, Inc., a medical device company specializing in orthotics,
is hoping to become the first Regulation A+ issuer to be listed on
the New York Stock Exchange's small-cap market (NYSE MKT). In
its offering statement for a Regulation A+ offering, which has been
qualified by the SEC, Myomo disclosed its intent to apply to list
its common stock on the NYSE MKT.
Before Myomo may commence trading on the NYSE MKT, the offering
must be completed, Myomo must file a post-qualification amendment
to the offering statement and Form 8-A registration statement, and
the SEC must qualify such post-qualification amendment.
For more information, see
here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Finance and Banking from UK
FCA Updates Its Alternatives Supervisory Strategy
Travers Smith LLP
On 1 March 2024, the FCA issued an interim update (Update) to its August 2022 and February 2023 portfolio letters (Portfolio Letters) to alternative asset management firms setting out its updated supervisory priorities.
Inside The FCA: Insights From 3 Ex-Regulators
Norton Rose Fulbright Hong Kong
Leveraging our experience as three ex-regulators we discuss the insights that our different experiences at the FCA have provided and how we translate that to advising clients across the full...
Regulation Round Up
Proskauer Rose LLP
Welcome to the UK Regulation Round Up, a regular bulletin highlighting the latest developments in UK and EU financial services regulation.